膀胱影像报告和数据系统(VI-RADS)预测肌层浸润性膀胱癌新辅助帕博利珠单抗治疗结局
在PURE-01试验中,110例肌层浸润性膀胱癌患者于帕博利珠单抗治疗前后行膀胱多参数磁共振成像,由中心统一审阅(共220次检查)。帕博利珠单抗治疗后VI-RADS 0-3分是预测ypT≤1N0的唯一显著协变量(P<0.001),模型曲线下面积为0.90,且与更长无事件生存期(P<0.001)和总生存期(P=0.044)相关。
要点
- 帕博利珠单抗治疗后VI-RADS 0-3分预测ypT≤1N0响应(P<0.001),模型AUC为0.90。
- 治疗后VI-RADS 0-3分亦预测更长无事件生存期(P<0.001)和总生存期(P=0.044)。
- 治疗前VI-RADS 0-3分与4-5分之间,基线肿瘤的多个基因特征评分存在差异。
核心结论
- 帕博利珠单抗治疗后VI-RADS评分与病理降期和生存期强相关。
- VI-RADS评分具有不同的生物标志物特征。
- 这些结果表明VI-RADS正成为设计肌层浸润性膀胱癌下一代试验的重要工具。
研究设计与样本
- PURE-01试验(ClinicalTrials.gov标识符:NCT02736266)中,患者在接受根治性膀胱切除术前,于治疗前和治疗后(三周期帕博利珠单抗)行膀胱多参数磁共振成像分期。
- 共110例患者接受中心统一审阅的扫描(共220次多参数磁共振成像),治疗时间为2017年2月至2020年7月。
- 采用逻辑回归模型分析帕博利珠单抗治疗前后VI-RADS评分与ypT≤1N0及ypT0N0响应的关系,VI-RADS评分按0-3分(0=无疾病证据)与4-5分二分。
- 进行无事件生存期和总生存期分析,并将综合基因组分析和转录组全表达谱数据与VI-RADS评分匹配。
主要发现
- 在多变量分析中,帕博利珠单抗治疗前和治疗后VI-RADS 0-3分均是预测ypT≤1N0终点的唯一显著协变量,其中治疗后VI-RADS 0-3分预测ypT≤1N0响应的效应最强(P<0.001)。
- 该模型的曲线下面积为0.90。
- 帕博利珠单抗治疗后VI-RADS 0-3分亦预测更长无事件生存期(P<0.001)和总生存期(P=0.044)。
- 基线肿瘤的多个基因特征评分在帕博利珠单抗治疗前VI-RADS 0-3分与4-5分两类之间不同。
关键数值与推荐
- 帕博利珠单抗治疗后VI-RADS 0-3分预测ypT≤1N0响应(P<0.001),模型曲线下面积为0.90。
- 帕博利珠单抗治疗后VI-RADS 0-3分与更长无事件生存期相关(P<0.001)。
- 帕博利珠单抗治疗后VI-RADS 0-3分与更长总生存期相关(P=0.044)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the predictive capability of the pre- and post-pembrolizumab Vesical Imaging-Reporting and Data System (VI-RADS) to identify ypT0N0 or ypT≤1N0 response in muscle-invasive bladder cancer (MIBC) within the PURE-01 trial (ClinicalTrials.gov identifier: NCT02736266). PATIENTS AND METHODS: Patients were staged with bladder multiparametric magnetic resonance imaging (mpMRI) before and after treatment (three cycles of pembrolizumab) prior to radical cystectomy (RC). Logistic regression models were used to analyse the pre- and post- pembrolizumab VI-RADS against ypT≤1N0 and ypT0N0 response. The VI-RADS scores were dichotomised between 0 and 3 (0 = no evidence of disease) and 4-5. Event-free survival (EFS) and overall survival (OS) analyses were performed. Comprehensive genomic profiling and transcriptome-wide expression profiling data were matched with the VI-RADS scores. RESULTS: In total, 110 patients underwent centrally reviewed scans (N = 220 mpMRI), treated between February 2017 and July 2020. Both pre- and post-pembrolizumab VI-RADS 0-3 scores were the only significant covariates that predicted the ypT≤1N0 endpoint in multivariable analyses, and the strongest effect was seen with post-pembrolizumab VI-RADS 0-3 predicting the ypT≤1N0 response (P < 0.001). The area under the curve for this model was 0.90. Post-pembrolizumab VI-RADS 0-3 also predicted a longer EFS (P < 0.001) and OS (P = 0.044). The scores of several gene signatures from baseline tumours differed between the pre-pembrolizumab VI-RADS 0-3 and 4-5 categories. CONCLUSION: Post-pembrolizumab VI-RADS scores are strongly associated with pathological downstaging and survival. VI-RADS scores were also characterised by distinct biomarker features. These results indicate that the VI-RADS is emerging as an important tool for designing next-generation trials for MIBC.
引用
- Necchi A, Basile G, Gibb EA, et al. Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. BJU Int. 2023. PMID: 37803523. doi:10.1111/bju.16191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。